Mode
Text Size
Log in / Sign up
Phase 3 N=8,657 Diagnostic

Evaluation of Diagnostic HIV Ag/Ab Combo Assay

Human Immunodeficiency Viruses

Enrolled (actual)
8,657
Serious AEs
0.0%
Results posted
Aug 2010
Primary outcome: Primary: Architect HIV Combo Test Data for Clinical Specificity in Population at Low Risk for HIV Infection — 37; 14; 0; 6113 Blood Specimens

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
ARCHITECT HIV Ag/Ab Combo (Device)
Age
Pediatric, Adult, Older Adult
Sex
All
Sponsor
Abbott Diagnostics Division
Primary completion
Oct 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Architect HIV Combo Test Data for Clinical Specificity in Population at Low Risk for HIV Infection
37; 14; 0; 6113
PRIMARY
Architect HIV Combo Test Data for Clinical Sensitivity in HIV Positive Specimens
63; 1003; 201; 0; 0; 0
PRIMARY
Architect HIV Combo Test Data for Specificity and Sensitivity in Pregnant Female Population
0; 65; 448; 0
PRIMARY
Architect HIV Combo Test Data for Specificity and Sensitivity in Pediatric Population (From 2 up to 21 Years of Age)
0; 64; 1; 0; 0; 0
SECONDARY
Architect HIV Combo Test Data for Reactivity of Architect HIV Combo in Increased HIV Risk Populations
65; 83; 5; 6; 6; 0

Summary

To test blood specimens using a new investigational test that detects antigen and antibody to human immunodeficiency virus (HIV). Results will be compared to an approved HIV antibody test and supplemental testing performed to determine HIV status.

Eligibility Criteria

Normal Healthy Population:

Inclusion Criteria

  • Apparently healthy individual at the time of enrollment as affirmed by the subject

Exclusion Criteria

  • HIV infection as affirmed by the subject

Pregnant Female Population at Risk for HIV Infection:

Inclusion Criteria

  • Subject is a pregnant female
  • Subject has risk factor for HIV infection

Exclusion Criteria

  • HIV infection as affirmed by the subject

HIV-1 Positive Pregnant Female Subjects

Inclusion Criteria

  • Subject is a pregnant female in first, second, or third trimester
  • Subject must have documented HIV infection

Exclusion Criteria

  • None

HIV-1 Positive Pediatric Subjects

Inclusion Criteria

  • Subject must be 2 years to 16 years of age
  • Subject must have documented HIV infection (e.g., Western blot positive or HIV RNA positive/detectable)

Exclusion Criteria

  • None
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00933933). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search